Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option ...

Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free ...

US FDA approves anti-CD38 therapy, Sarclisa in combo with standard-of-care treatment for adult patients with NDMM who are not eligible for transplant: Paris Tuesday, September 24, ...

New updates on the understanding of the link between low-dose ionising radiation and mortality from haematological ...

During a Case-Based Roundtable® event, Samer A. Al'Hadidi, MD, MS, discussed the CARTITUDE-4 trial of cilta-cel in patients with relapsed/refractory multiple myeloma in the first article of a 2-part ...

Global real-world data support the use of autologous hematopoietic stem cell transplant in patients with newly diagnosed multiple myeloma, according to researchers.

Researchers sought to determine whether fixed-duration therapy would still be feasible for patients with RRMM who were treated with a bispecific antibody in clinical trials and discontinued.

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. /PRNewswire/ -- USA News Group – Cancer rates are rising glob ...

The cost of cancer medication and treatment is out of the reach of many patients in the country, leading to the condition ...

The modified cells recognise and bind to B-cell maturation antigen (BCMA), a protein that is nearly universally expressed on cancer cells in multiple myeloma, leading to the death of cells ...

India’s first mpox case, and what it means for the country’s public health landscape, a new senior citizen health cover ...